FDA approves Cidara's Rezzayo as antifungal treatment for candidemia and invasive candidiasis
Cidara Therapeutics’ antifungal Rezzayo (rezafungin) has been approved by the FDA under priority review for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options, the company announced Wednesday.
While the EMA accepted the marketing authorization application for rezafungin in August 2022, it is still under review for potential approval in Europe.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.